Determine the necessary mass, volume, or concentration for preparing a solution.
Simtuzumab (anti-LOXL2) (Ab170556) - ELISA
Immobilized hu-LOXL2-his at 2 μg/mL can bind Simtuzumab (anti-LOXL2) (Ab170556) with the EC₅₀ of 38.57 ng/mL.
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
Ab170556-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $59.90 | |
Ab170556-1mg | 1mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $267.90 | |
Ab170556-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $657.90 | |
Ab170556-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,047.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
Product Name | Simtuzumab (anti-LOXL2), for ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt various applications, specific to LOXL2, >95%, high purity, Human IgG4SP |
---|---|
Synonyms | EC 1.4.3.13 | Lysyl oxidase-like protein 2 | Lysyl oxidase-related protein 2 | Lysyl oxidase-related protein WS9-14 |
Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
Host species | Human |
Specificity | LOXL2 |
Application | ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt |
Conjugation | Unconjugated |
Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of lysyl oxidase like 2 |
Product Description | Simtuzumab (anti-LOXL2) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab (anti-LOXL2) can be used for the research of primary sclerosing cholangitis (PSC). Purity: >95% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg |
Antibody Type | Primary antibody |
---|---|
Clonality | Recombinant |
Isotype | Human IgG4SP |
Light Chain Type | kappa |
SDS-PAGE | 27.3 kDa (Light Chain) & 52.7 kDa (Heavy Chain), under reducing conditions; 180.0 kDa, under non-reducing conditions. |
Purification Method | Protein A purified |
Purity | >95% |
Source | CHO supernatant |
Form | Liquid |
Concentration | See COA |
Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
Shipped In | Ice chest + Ice pads |
Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
CAS | 1318075-13-6 |
Simtuzumab (anti-LOXL2) (Ab170556) - ELISA
Immobilized hu-LOXL2-his at 2 μg/mL can bind Simtuzumab (anti-LOXL2) (Ab170556) with the EC₅₀ of 38.57 ng/mL.
Simtuzumab (anti-LOXL2) (Ab170556) - SEC
The purity of Simtuzumab (anti-LOXL2) (Ab170556) is more than 95% verified by HPLC.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|---|---|---|---|---|---|---|
Lysyl oxidase homolog 2 inhibitor | INHIBITOR | ALA3714029 | Lysyl oxidase homolog 2 | SINGLE PROTEIN | Homo sapiens | PubMed: [1] | |
Lysyl oxidase homolog 2 inhibitor | INHIBITOR | ALA3714029 | Lysyl oxidase homolog 2 | SINGLE PROTEIN | Homo sapiens | PubMed: [1] |
Find and download the COA for your product by matching the lot number on the packaging.
2 results found
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
ZJ23F1001455 | Certificate of Analysis | Oct 26, 2023 | Ab170556 |
ZJ23F1001456 | Certificate of Analysis | Oct 26, 2023 | Ab170556 |
1. Rodriguez HM, Vaysberg M, Mikels A, McCauley S, Velayo AC, Garcia C, Smith V. (2010) Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor.. J Biol Chem, 285 (27): (20964-74). [PMID:20439985] [10.1021/op500134e] |
2. Nishioka T, Eustace A, West C. (2012) Lysyl oxidase: from basic science to future cancer treatment.. Cell Struct Funct, 37 (1): (75-80). [PMID:22453058] [10.1021/op500134e] |
3. Cano A, Santamaría PG, Moreno-Bueno G. (2012) LOXL2 in epithelial cell plasticity and tumor progression.. Future Oncol, 8 (9): (1095-108). [PMID:23030485] [10.1021/op500134e] |
4. Adamali HI, Maher TM. (2012) Current and novel drug therapies for idiopathic pulmonary fibrosis.. Drug Des Devel Ther, 6 (13): (261-72). [PMID:23055696] [10.1021/op500134e] |
5. Tadmor T, Bejar J, Attias D, Mischenko E, Sabo E, Neufeld G, Vadasz Z. (2013) The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.. Am J Hematol, 88 (5): (355-8). [PMID:23494965] [10.1021/op500134e] |
6. Van Bergen T, Marshall D, Van de Veire S, Vandewalle E, Moons L, Herman J, Smith V, Stalmans I. (2013) The role of LOX and LOXL2 in scar formation after glaucoma surgery.. Invest Ophthalmol Vis Sci, 54 (8): (5788-96). [PMID:23821193] [10.1021/op500134e] |
7. Chien JW, Richards TJ, Gibson KF, Zhang Y, Lindell KO, Shao L, Lyman SK, Adamkewicz JI, Smith V, Kaminski N et al.. (2014) Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression.. Eur Respir J, 43 (5): (1430-8). [PMID:24177001] [10.1021/op500134e] |
8. Martin A, Salvador F, Moreno-Bueno G, Floristán A, Ruiz-Herguido C, Cuevas EP, Morales S, Santos V, Csiszar K, Dubus P et al.. (2015) Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression.. EMBO J, 34 (8): (1090-109). [PMID:25759215] [10.1021/op500134e] |
9. Smithen DA, Leung LMH, Challinor M, Lawrence R, Tang H, Niculescu-Duvaz D, Pearce SP, Mcleary R, Lopes F, Aljarah M et al.. (2020) 2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth.. J Med Chem, 63 (5): (2308-2324). [PMID:31430136] [10.1021/op500134e] |
10. Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, Evans HR, Gartland A, Erler JT. (2011) LOXL2-mediated matrix remodeling in metastasis and mammary gland involution.. Cancer Res, 71 (5): (1561-72). [PMID:21233336] [10.1021/op500134e] |
11. Hajdú I, Kardos J, Major B, Fabó G, Lőrincz Z, Cseh S, Dormán G.. (2018) Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.. Bioorg Med Chem Lett, 28 (18): (3113-3118). [PMID:30098867] [10.1016/j.bmcl.2018.07.001] |
12. Saito, H H, Papaconstantinou, J J, Sato, H H and Goldstein, S S.. (1997) Regulation of a novel gene encoding a lysyl oxidase-related protein in cellular adhesion and senescence.. The Journal of biological chemistry, (28): [PMID:9079631] |
13. Jourdan-Le Saux, C C and 5 more authors.. (1999) The LOXL2 gene encodes a new lysyl oxidase-like protein and is expressed at high levels in reproductive tissues.. The Journal of biological chemistry, (30): [PMID:10212285] |
14. Peinado, Héctor H and 8 more authors.. (2005) A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression.. The EMBO journal, (5): [PMID:16096638] |
15. Nusbaum, Chad C and 75 more authors.. (2006) DNA sequence and analysis of human chromosome 8.. Nature, (19): [PMID:16421571] |
16. Schietke, Ruth R and 10 more authors.. (2010) The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1.. The Journal of biological chemistry, (26): [PMID:20026874] |
17. Kim, Young-Mi YM, Kim, Eun-Cheol EC and Kim, Youngho Y.. (2011) The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin.. Molecular biology reports, [PMID:20306300] |
18. Barry-Hamilton, Vivian V and 22 more authors.. (2010) Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment.. Nature medicine, [PMID:20818376] |
19. Moreno-Bueno, Gema G and 16 more authors.. (2011) Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas.. EMBO molecular medicine, [PMID:21732535] |
20. Bignon, Marine M and 15 more authors.. (2011) Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and type IV collagen assembly in the endothelial basement membrane.. Blood, (6): [PMID:21835952] |
21. Lugassy, Jennie J and 6 more authors.. (2012) The enzymatic activity of lysyl oxidas-like-2 (LOXL2) is not required for LOXL2-induced inhibition of keratinocyte differentiation.. The Journal of biological chemistry, (27): [PMID:22157764] |
22. Li, Tian-Yu TY and 8 more authors.. (2012) Reduced nuclear and ectopic cytoplasmic expression of lysyl oxidase-like 2 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma.. Human pathology, [PMID:22204712] |
23. Xu, Li L and 7 more authors.. (2013) Post-translational modifications of recombinant human lysyl oxidase-like 2 (rhLOXL2) secreted from Drosophila S2 cells.. The Journal of biological chemistry, (22): [PMID:23319596] |
24. Millanes-Romero, Alba A and 8 more authors.. (2013) Regulation of heterochromatin transcription by Snail1/LOXL2 during epithelial-to-mesenchymal transition.. Molecular cell, (12): [PMID:24239292] |
25. Cuevas, Eva P EP and 5 more authors.. (2014) LOXL2 catalytically inactive mutants mediate epithelial-to-mesenchymal transition.. Biology open, (15): [PMID:24414204] |
26. Iturbide, Ane A and 6 more authors.. (2015) LOXL2 Oxidizes Methylated TAF10 and Controls TFIID-Dependent Genes during Neural Progenitor Differentiation.. Molecular cell, (4): [PMID:25959397] |
27. Sasaki, Takako T and 10 more authors.. (2016) Functional consequence of fibulin-4 missense mutations associated with vascular and skeletal abnormalities and cutis laxa.. Matrix biology : journal of the International Society for Matrix Biology, [PMID:27339457] |
28. Herranz, Nicolás N and 12 more authors.. (2016) Lysyl oxidase-like 2 (LOXL2) oxidizes trimethylated lysine 4 in histone H3.. The FEBS journal, [PMID:27735137] |
29. Cuevas, Eva P EP and 6 more authors.. (2017) LOXL2 drives epithelial-mesenchymal transition via activation of IRE1-XBP1 signalling pathway.. Scientific reports, (23): [PMID:28332555] |
30. Zhang, Xi X and 5 more authors.. (2018) Crystal structure of human lysyl oxidase-like 2 (hLOXL2) in a precursor state.. Proceedings of the National Academy of Sciences of the United States of America, (10): [PMID:29581294] |